Katy Medicine and Shenghe Pharmaceuticals Sign Strategic Cooperation Agreement
Nanjing Kati Medicine April 16
Katy Medical and Shenghe Pharmaceuticals signed a strategic cooperation agreement Nanjing Katy Medical April 16, 2020, April 15, 2020, Nanjing Katy Medical Technology Co., Ltd. (hereinafter referred to as Katy Medical) and Nanjing Shenghe Pharmaceutical Co., Ltd. (Hereinafter referred to as Shenghe Pharmaceutical) signed a strategic cooperation agreement in the Medical Valley of Jiangbei New Area, Nanjing. Chairman Wang Enxiu of Kati Medicine, Deputy General Manager of Shenghe Pharmaceutical and Dean of Research Institute Zhao Liwen signed a strategic cooperation agreement on behalf of both companies, and Luo Shuqin, Deputy Director of Life and Health Office of Jiangbei New District, Nanjing witnessed the signing.
Address by Wang Enxiu, Chairman of Katy Medical
This signing is the beginning of cooperation between the two parties. In the future, both parties will use this as a starting point to gradually upgrade the level of strategic cooperation and achieve win-win development.
Speech by Zhao Liwen, Deputy General Manager and Dean of Research Institute of Shenghe Pharmaceutical
Shenghe Pharmaceutical cherishes this opportunity to cooperate with Katy Medicine, and believes that this cooperation will promote the rapid development of tumor immunotherapy technology.
Speech by Luo Shuqin, Deputy Director of Life and Health Office of Jiangbei New Area
Nanjing Biomedicine Valley relies on the national major new drug creation and major scientific and technological achievements transfer pilot demonstration base to forge ahead and strive to become a source of innovation in the pharmaceutical field. It has now gathered together including Katy Medicine, Simcere TECO, Luye Pharma, Nanwei Medicine, and Jianyou Biochemical etc.There are more than 800 companies related to the health industry chain. It is hoped that through the strategic cooperation between Katy Medicine and Shenghe Pharmaceutical, the continuous innovation of CAR-T treatment technology will be promoted; with the smooth development of the strategic cooperation between the two parties, more people will enjoy health and happiness in the future.
Through this strategic cooperation, both parties will achieve complementary advantages and strong alliances, and jointly build a new chapter in the development of tumor immunotherapy technology!
